Prostate-specific antigen change in the european randomized study of screening for prostate cancer, section rotterdam

Urology

Volumn 63, Issue 2, 2004, Pages 316-320

  Raaijmakers, René ^a   Wildhagen, Mark F ^b   Ito, Kazuto ^b   Pàez, Alvaro ^b   De Vries, Stijn H ^b   Roobol, Monique J ^b   Schröder, Fritz H ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CALCULATION; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EARLY DIAGNOSIS; EUROPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY;

EID: 1242341917     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2003.09.028     Document Type: Article

References (19)

1. Schöder F.H., Denis L.J., Kirkels W., et al. European Randomized Study of Screening for Prostate Cancer Progress report of Antwerp and Rotterdam pilot studies . Cancer. 76:1995;129-134.
2. Rietbergen J.B., Kranse R., Kirkels W.J., et al. Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer improving the efficiency of early detection . Br J Urol. 79:(suppl 2):1997;57-63.
3. Kranse R., Beemsterboer P., Rietbergen J., et al. Predictors for biopsy outcome in the European Randomized Study of Screening for Prostate Cancer (Rotterdam region). Prostate. 39:1999;316-322.
4. Beemsterboer P.M., Kranse R., de Koning H.J., et al. Changing role of 3 screening modalities in the European Randomized Study of Screening for Prostate Cancer (Rotterdam). Int J Cancer. 84:1999;437-441.
5. Roobol MJ, Kranse R, and Schröder FH: Value of PSA velocity as a screening tool for prostate cancer at low PSA levels (i.e., PSA <4 ng/ml): results of the second screening round of ERSPC (Rotterdam). Urology (in press).
6. Raaijmakers R., Blijenberg B.G., Schröder F.H. Prostate cancer detection in the PSA range 2-3 ng/ml value of PSA, fPSA, hK2 and related algorithms . (abstract) J Urol. 167:2002;287.
7. Yurdakul G., Bangma C.H., Blijenberg B.G., et al. Different PSA assays lead to detection of prostate cancers with identical histological features. Eur Urol. 42:2002;154-158.
8. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 267:1992;2215-2220.
9. Smith D.S., Catalona W.J. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol. 152:1994;1163-1167.
10. Brawer M.K., Beatie J., Wener M.H., et al. Screening for prostatic carcinoma with prostate specific antigen results of the second year . J Urol. 150:1993;106-109.
11. Schöder F.H., Kranse R., Barbet N., et al. Prostate-specific antigen a surrogate endpoint for screening new agents against prostate cancer? Prostate. 42:2000;107-115.
12. Carter H.B., Morrell C.H., Pearson J.D., et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 52:1992;3323-3328.
13. Stephenson A.J., Aprikian A.G., Souhami L., et al. Utility of PSA doubling time in follow-up of untreated patients with localized prostate cancer. Urology. 59:2002;652-656.
14. Kakehi Y., Kamoto T., Shiraishi T., et al. Correlation of initial PSA level and biopsy features with PSA-doubling time in early stage prostate cancers in Japanese men. Eur Urol. 41:2002;47-53.
15. Choo R., DeBoer G., Klotz L., et al. PSA doubling time of prostate carcinoma managed with watchful observation alone. Int J Radiat Oncol Biol Phys. 50:2001;615-620.
16. Komatsu K., Wehner N., Prestigiacomo A.F., et al. Physiologic (intraindividual) variation of serum prostate-specific antigen in 814 men from a screening population. Urology. 47:1996;343-346.
17. Prestigiacomo A.F., Stamey T.A. Physiological variation of serum prostate specific antigen in the 4.0 to 10.0 ng./ml. range in male volunteers. J Urol. 155:1996;1977-1980.
18. Carter H.B., Pearson J.D., Waclawiw Z., et al. Prostate-specific antigen variability in men without prostate cancer effect of sampling interval on prostate-specific antigen velocity . Urology. 45:1995;591-596.
19. Lujan M., Paez A., Sanchez E., et al. Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol. 162:1999;1311-1313.